NCT04021173View on ClinicalTrials.gov

A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)

PHASE2UnknownINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

November 30, 2021

Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
DRUG

Anfibatide

5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion

DRUG

Placebos

5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion

Trial Locations (1)

Unknown

Shanghai Ruijing Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Lee's Pharmaceutical Limited

INDUSTRY